| Literature DB >> 36235085 |
Sachin A Deodware1,2, Umesh B Barache3, Pratibha C Dhale2, Kundalkesha D Gaikwad2, Chandan Shivamallu4, Panchsheela A Ubale5, Ali A Shati6, Mohammad Y Alfaifi6, Serag Eldin I Elbehairi6,7, Raghu Ram Achar8, Ekaterina Silina9, Victor Stupin9, Juan Frau10, Norma Flores-Holguín11, Shashikant H Gaikwad2, Shiva Prasad Kollur12, Daniel Glossman-Mitnik11.
Abstract
Herein we describe the synthesis of a series of nickel(II) complexes (C1-C3) with Schiff bases (HL1-HL3) derived from 4-amino-5-mercapto-3-methyl-1,2,4-triazole and ortho/meta/para-nitrobenzaldehyde having composition [Ni(L)2(H2O)2]. The obtained ligands and their complexes were characterized using physico-chemical techniques viz., elemental analysis, magnetic moment study, spectral (electronic, FT-IR, 1H-NMR) and thermal analysis. The elemental analysis and spectral analysis revealed that Schiff bases behave as monoanionic bidentate ligands towards the Ni(II) ion. Whereas, the magnetic moment study suggested the octahedral geometry of all the Ni(II) complexes. The thermal behavior of the complexes has been studied by thermogravimetric analysis and agrees well with the composition of complexes. Further, the biological activities such as antimicrobial and antifungal studies of the Schiff bases and Ni(II) complexes have been screened against bacterial species (Staphylococcus aureus and Pseudomonas aeruginosa) and fungal species (Aspergillus niger and Candida albicans) activity by MIC method, the results of which revealed that metal complexes exhibited significant antimicrobial activities than their respective ligands against the tested microbial species. Furthermore, the molecular docking technique was employed to investigate the active sites of the selected protein, which indeed helped us to screen the potential anticancer agents among the synthesized ligand and complexes. Further, these compounds have been screened for their in vitro anticancer activity using OVCAR-3 cell line. The results revealed that the complexes are more active than the ligands.Entities:
Keywords: Nickel(II) complexes; anticancer screening; antimicrobial studies; conceptual DFT; molecular docking
Mesh:
Substances:
Year: 2022 PMID: 36235085 PMCID: PMC9570899 DOI: 10.3390/molecules27196548
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.927
Scheme 1General route of synthesis of Schiff base ligand and respective Ni(II) metal complexes.
Physical and analytical data of ligands and metal complexes.
| Sl. | Name of Comp. | Mol. | Mol. | Color | Elemental Analysis | |||
|---|---|---|---|---|---|---|---|---|
| C% | H% | N% | M% | |||||
| 1 | HL1 | C10H9N5SO2 | 263 | Pale yellow | 45.20 | 3.52 | 26.48 | - |
| 2 | C1 | C20H20N10S2O6Ni | 618.69 | green | 38.71 (38.78) | 3.30 (3.23) | 22.58 (22.62) | 9.59 (9.52) |
| 3 | HL2 | C10H9N5SO2 | 263 | Yellow | 45.78 | 3.45 | 26.70 | - |
| 4 | C2 | C20H20N10S2O6Ni | 618.69 | green | 38.66 (38.78) | 3.31 (3.23) | 22.71 (22.62) | 9.61 (9.52) |
| 5 | HL3 | C10H9N5SO2 | 263 | Dark | 45.52 | 3.55 | 26.65 | - |
| 6 | C3 | C20H20N10S2O6Ni | 618.69 | Yellow green | 38.70 (38.78) | 3.28 (3.23) | 22.49 (22.62) | 9.40 (9.52) |
Figure 1The molecular structures of triazol-based Schiff base ligands (HL1–HL3).
FT-IR spectral data of ligands and metal complexes (cm−1).
| Sl. No. | Compd. | νC = N | νSH | νC = S | νN-H | νH2O | νM-S | νM-N |
|---|---|---|---|---|---|---|---|---|
| 1 | HL1 | 1590 | 2760 | 1114 | 3067 | - | - | - |
| 2 | C1 | 1525 | - | - | - | 3206 | 379 | 483 |
| 3 | HL2 | 1589 | 2753 | 1176 | 3072 | - | - | - |
| 4 | C2 | 1568 | - | - | - | 3311 | 332 | 491 |
| 5 | HL3 | 1579 | 2770 | 1170 | 3096 | - | - | - |
| 6 | C3 | 1552 | - | - | - | 3200 | 379 | 483 |
Electronic and magnetic moment studies of complexes.
| Complex | γ1 (nm) | γ2 (nm) | γ3 (nm) | µ Eff. (BM) |
|---|---|---|---|---|
| C1 | 1011 | 620 | 400 | 3.45 |
| C2 | 990 | 580 | 400 | 3.23 |
| C3 | 1012 | 616 | 401 | 3.34 |
Stepwise thermal degradation of metal complexes (C1–C3).
| Compound | Stages | Temp. | TG Mass % | Assignment | |
|---|---|---|---|---|---|
| Calc. | Found | ||||
| C1 | 1 | 50–180 | 5.81 | 6.92 | -2.H2O (water molecules) |
| C2 | 1 | 50–190 | 5.81 | 6.90 | -2.H2O (water molecules) |
| C3 | 1 | 50–165 | 5.81 | 6.71 | -2.H2O (water molecules) |
X-ray parameters of HL1, HL2, HL3 and C3.
| Sl. No. | Parameter | HL1 | HL2 | HL3 | C3 |
|---|---|---|---|---|---|
| 1 | Structure | Orthorhombic | Orthorhombic | Orthorhombic | Orthorhombic |
| 2 | Space group |
|
|
|
|
| 3 | Symmetry of lattice | Primitive | Primitive | Body centered | Primitive |
| 4 | Bond angle | α = β = γ = 90° | α = β = γ = 90° | α = β = γ = 90° | α = β = γ = 90° |
| 5 | Lattice parameters | a = 16.61 | a = 14.40 | a = 10.83 | a = 11.89 |
| 6 | Volume of the cell | 529.96 | 1927.23 | 1343.12 | 1987.79 |
| 7 | Density (g/cc) Theoretical | 0.8239 | 0.2265 | 0.65 | 0.52 |
| 8 | No. of molecules/unit cell (η) | 1 | 1 | 2 | 1 |
| 9 | Pore fraction | 0.0853 | 0.1099 | 0.0599 | 0.0961 |
| 10 | Crystallite size (Å) | 337 | 169 | 337 | 235 |
| 11 | Micro strain (×10−3) | 1.2649 | 219 | 1.024 | 1.376 |
Frontier Orbital Energies, HOMO-LUMO Gap and the KID Descriptors of the Ligand Descriptors and their Ni(II) Complexes.
| Compound | HOMO | LUMO | SOMO | H-L Gap | J | J | J | ∆SL |
|---|---|---|---|---|---|---|---|---|
| HL1 | −6.31 | −3.12 | −2.69 | 3.19 | 0.25 | 0.23 | 0.34 | 0.43 |
| HL2 | −6.28 | −2.89 | −2.56 | 3.39 | 0.24 | 0.19 | 0.31 | 0.33 |
| HL3 | −6.30 | −3.05 | −2.73 | 3.25 | 0.24 | 0.17 | 0.21 | 0.31 |
| C1 | −5.17 | −3.19 | −2.87 | 1.98 | 0.45 | 0.18 | 0.48 | 0.32 |
| C2 | −5.66 | −3.03 | −2.83 | 2.63 | 0.13 | 0.11 | 0.17 | 0.21 |
| C3 | −5.77 | −3.04 | −2.85 | 2.73 | 0.14 | 0.10 | 0.17 | 0.19 |
Global Reactivity Descriptors of the Ligands and their Ni(II) Complexes.
| Compound |
| η | ω | S | N | ω− | ω+ | Δ ω± |
|---|---|---|---|---|---|---|---|---|
| HL1 | 4.72 | 3.19 | 3.47 | 0.31 | 2.48 | 9.53 | 4.81 | 14.35 |
| HL2 | 4.59 | 3.39 | 3.10 | 0.29 | 2.51 | 8.70 | 4.12 | 12.82 |
| HL3 | 4.67 | 3.25 | 3.36 | 0.31 | 2.50 | 9.25 | 4.58 | 13.84 |
| C1 | 4.18 | 1.98 | 4.41 | 0.51 | 3.63 | 11.03 | 6.85 | 17.88 |
| C2 | 4.35 | 2.63 | 3.60 | 0.38 | 3.13 | 9.53 | 5.18 | 14.71 |
| C3 | 4.40 | 2.73 | 3.55 | 0.37 | 3.02 | 9.47 | 5.06 | 14.53 |
Antimicrobial activity of Schiff bases and their Ni(II) complexes.
| Sr. | Compd. | Conc.mg mL−1 |
|
|
|
|
|---|---|---|---|---|---|---|
| 1 | HL1 | 0.2 | +++ | +++ | - | - |
| 2 | HL1-Ni | 0.2 | +++ | +++ | - | - |
| 3 | HL2 | 0.2 | - | ++ | - | ++ |
| 4 | HL2-Ni | 0.2 | - | ++ | - | - |
| 5 | HL3 | 0.2 | + | ++ | - | - |
| 6 | HL3-Ni | 0.2 | - | ++ | - | - |
Less than 5 mm = Inactive (-), 6–10 mm = Weakly active (+), 11–14 mm = Moderately. Active (++), 15 mm and above = Highly active (+++).
Figure 2(a) Zone of inhibition of HL2 and HL2-Ni for Pseudomonas aeruginosa; (b) Zone of inhibition of HL3 and HL3 -Ni for Staphylococcus aureus.
Binding Interaction of Schiff bases and their Ni(II) complexes.
| Sr. No. | Molecule Code | B. E. | Interaction with Amino Acid | ||
|---|---|---|---|---|---|
| H Bond | Charge | Hydrophobic | |||
| 1 | HL1 | −40.52 | GLN22 | --- | LYS41, VAL36 |
| 2 | C1 | −84.53 | ASN142 | GLU99, ASP97 | GLY21, GLU99 |
| 3 | HL2 | −47.89 | PHE23, SER97 | π stackang-TRP43, PHE51, PHE122 | LEU144, GLU121, PHE122, ALA125 |
| 4 | C2 | −96.35 | ASN142 | GLU99, | LYS103, ASN144 |
| 5 | HL3 | −47.89 | PHE23 | --- | LEU144, LYS41 |
| 6 | C3 | −88.76 | LYS139 | ASP97 | LYS139, VAL100 |
* VDW-van der Waals forces.
Figure 3Interactions of (a) HL1 and (b) C1 with amino acids (LYS41 and VAL36).
Figure 4Growth curve for human ovarian cancer cell line OVCAR-3 for Schiff bases and their Ni(II) complexes.
Preliminary in vitro anticancer screening data of Schiff bases (HL1–HL3) and their complexes (C1–C3).
| Conc. | Average Values for % Control Growth | ||||||
|---|---|---|---|---|---|---|---|
| HL1 | C1 | HL2 | C2 | HL3 | C3 | Adriamycin | |
| 10−7 | 124.1 | 122.4 | 157.9 | 139.2 | 51.1 | 109.7 | 43.2 |
| 10−6 | 144 | 125.3 | 173.4 | 127.6 | 129.1 | 101.8 | 3.6 |
| 10−5 | 130.6 | 113.9 | 158.3 | 144.4 | 119.2 | 93.5 | −53.9 |
| 10−4 | 73.4 | 12.7 | 90.9 | 4.8 | 85.4 | 55.1 | −55.6 |
Figure 5Correlation plot of binding energy and GI50 for C1 and C2.